Business context and reporting period
Alterity Therapeutics Limited, a development-stage enterprise, filed this Form 6-K as a foreign private issuer for October 2026. The report was signed on October 9, 2026. The filing identifies the company’s principal executive office in Melbourne, Australia, and indicates it reports annually on Form 20-F.
Filing contents
The filing lists Exhibit 99.1, “Alterity to Present at Canaccord Drug and Device Conference.” The exhibit’s contents are not included in the supplied filing text, so details of the presentation are not available here.
Financial performance and material changes
This Form 6-K provides no revenue, profit, cash flow, margin, debt, liquidity, or other financial results, and no comparative-period figures or material financial changes.
Outlook, risks, and other items
No guidance, outlook, management commentary, risks, contingencies, or unusual financial items are described in the supplied text. The filing states that it is incorporated by reference into specified Form S-8 and Form F-3 registration statements.
Important facts to verify
- Review Exhibit 99.1 for the conference presentation announcement and any additional disclosures.
- Confirm the reporting period: the request metadata specifies October 31, 2026, while the filing identifies October 2026 and is dated October 9, 2026.
- Consult the company’s financial reports for current financial results, liquidity, and risks; this filing does not provide those details.